Richard Pestell
Richard Pestell
CEO and Founder -ProstaGene, StromaGenesis, EcoGenome, ioROC, Shenandoah Pharmaceuticals
Embedded Files
Richard Pestell’s medical journey began at the University of Western Australia, where he graduated at the top of his class, earning an M.B., B.S. His subsequent training as a physician in training at the Royal Perth Hospital and St Vincent's Hospital, Sydney, provided a demanding and broad experience in Internal Medicine and residency. During these formative years, he worked across oncology, endocrinology, hematology, cardiology, and transplant medicine, building a clinical foundation that later supported his work in research and academic medicine, guided by a commitment to advancing patient care.
Richard Pestell’s medical journey began at the University of Western Australia, where he graduated at the top of his class, earning an M.B., B.S. His subsequent training as a physician in training at the Royal Perth Hospital and St Vincent's Hospital, Sydney, provided a demanding and broad experience in Internal Medicine and residency. During these formative years, he worked across oncology, endocrinology, hematology, cardiology, and transplant medicine, building a clinical foundation that later supported his work in research and academic medicine, guided by a commitment to advancing patient care.
His interest in cancer biology led him to research the underlying mechanisms of disease. He completed a Ph.D. at the University of Melbourne's Howard Florey Institute, specializing in the regulation of oncogene transcription. This research training helped him develop a disciplined approach to studying cancer biology while remaining grounded in questions relevant to patient care, where science often examines the processes driving disease.
His interest in cancer biology led him to research the underlying mechanisms of disease. He completed a Ph.D. at the University of Melbourne's Howard Florey Institute, specializing in the regulation of oncogene transcription. This research training helped him develop a disciplined approach to studying cancer biology while remaining grounded in questions relevant to patient care, where science often examines the processes driving disease.
Richard’s academic excellence was recognized through national scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award. These recognitions supported his move to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow. This phase strengthened his ability to connect clinical practice with research goals, advancing progress in oncology and translational medicine.
Richard’s academic excellence was recognized through national scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award. These recognitions supported his move to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow. This phase strengthened his ability to connect clinical practice with research goals, advancing progress in oncology and translational medicine.
Academic Leadership and Scientific Influence
Academic Leadership and Scientific Influence
Richard Pestell continued his academic career at Northwestern University and later at the Albert Einstein College of Medicine. He became a Professor, Chair of the Division of Endocrine-Dependent Tumor Biology, and Co-Director of major cancer research programs. In addition, he held positions at multiple hospitals in New York, allowing him to remain engaged in patient care and medical education while also supporting research direction and faculty development.
Richard Pestell continued his academic career at Northwestern University and later at the Albert Einstein College of Medicine. He became a Professor, Chair of the Division of Endocrine-Dependent Tumor Biology, and Co-Director of major cancer research programs. In addition, he held positions at multiple hospitals in New York, allowing him to remain engaged in patient care and medical education while also supporting research direction and faculty development.
His research contributed to scientific knowledge that informed cancer therapeutics. His research on cyclin D1 was cited in seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. He approached these efforts with an emphasis on careful research practices, clear interpretation, and relevance to clinical needs, through sustained scientific rigor.
His research contributed to scientific knowledge that informed cancer therapeutics. His research on cyclin D1 was cited in seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. He approached these efforts with an emphasis on careful research practices, clear interpretation, and relevance to clinical needs, through sustained scientific rigor.
He also produced work on CCR5 that provided a scientific framework for current oncology clinical trials with CCR5 inhibitors. Throughout his career, he has published over 700 works, received more than 110,000 citations, and achieved an h-index of 162. He has also given numerous invited lectures worldwide, reflecting his ongoing participation in international scientific exchange and collaboration.
He also produced work on CCR5 that provided a scientific framework for current oncology clinical trials with CCR5 inhibitors. Throughout his career, he has published over 700 works, received more than 110,000 citations, and achieved an h-index of 162. He has also given numerous invited lectures worldwide, reflecting his ongoing participation in international scientific exchange and collaboration.
Directing Major Cancer Centers
Directing Major Cancer Centers
Richard Pestell became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University in 2002. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In these roles, he was responsible for research direction, clinical operations, and faculty development, and he contributed to institutional restructuring and growth to strengthen cancer center programs and long-term capacity.
Richard Pestell became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University in 2002. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In these roles, he was responsible for research direction, clinical operations, and faculty development, and he contributed to institutional restructuring and growth to strengthen cancer center programs and long-term capacity.
He worked to build community partnerships, enhance research programs, and expand clinical services across Georgetown and MedStar systems. These efforts required balancing clinical needs with research planning and institutional operations, while also supporting collaboration among teams and strengthening patient care delivery.
He worked to build community partnerships, enhance research programs, and expand clinical services across Georgetown and MedStar systems. These efforts required balancing clinical needs with research planning and institutional operations, while also supporting collaboration among teams and strengthening patient care delivery.
Richard became the Director of the Sidney Kimmel Cancer Center in 2005. Also, he served as Chair of the Department of Cancer Biology and head of the Oncology Service Line at Thomas Jefferson University. These leadership responsibilities broadened his work across cancer research, education, and clinical services, with a focus on coordinated strategy and sustainable program development.
Richard became the Director of the Sidney Kimmel Cancer Center in 2005. Also, he served as Chair of the Department of Cancer Biology and head of the Oncology Service Line at Thomas Jefferson University. These leadership responsibilities broadened his work across cancer research, education, and clinical services, with a focus on coordinated strategy and sustainable program development.
He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. Under his tenure, the cancer center rose from 64 to 17, reflecting measurable progress across a large and complex cancer enterprise.
He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. Under his tenure, the cancer center rose from 64 to 17, reflecting measurable progress across a large and complex cancer enterprise.
Academic Appointments and Global Engagement
Academic Appointments and Global Engagement
Richard Pestell has also held leadership roles in academia outside of the US, supporting efforts that connect research, education, and global outreach. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. These roles reflect continued attention to building partnerships and strengthening access to training and cancer programs.
Richard Pestell has also held leadership roles in academia outside of the US, supporting efforts that connect research, education, and global outreach. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. These roles reflect continued attention to building partnerships and strengthening access to training and cancer programs.
He has served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions. Through these affiliations, he has supported academic collaboration and advisory work across diverse educational and research environments.
He has served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions. Through these affiliations, he has supported academic collaboration and advisory work across diverse educational and research environments.
Richard’s election to and service with prominent scientific bodies reflect the global reach of his work. He has served at the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019.
Richard’s election to and service with prominent scientific bodies reflect the global reach of his work. He has served at the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019.
Building Companies and Advancing Innovation
Building Companies and Advancing Innovation
Richard Pestell has combined academic leadership with entrepreneurship in the biotechnology sector. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors, plus more than 80 million dollars as a principal investigator on NIH research grants, supporting the development of research-driven innovation.
Richard Pestell has combined academic leadership with entrepreneurship in the biotechnology sector. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors, plus more than 80 million dollars as a principal investigator on NIH research grants, supporting the development of research-driven innovation.
His patent portfolio has included discoveries in molecular diagnostics, cancer prognostics, therapeutic methods, and novel technologies that have impacted academic and commercial drug discovery and development. He has served in advisory capacities for organizations such as the National Academy of Inventors, CytoDyn, Novartis, Deloitte, and numerous health technology companies. Through these roles, he has focused on translating research into practical tools and methods that support improved diagnostics, treatment development, and research strategy.
His patent portfolio has included discoveries in molecular diagnostics, cancer prognostics, therapeutic methods, and novel technologies that have impacted academic and commercial drug discovery and development. He has served in advisory capacities for organizations such as the National Academy of Inventors, CytoDyn, Novartis, Deloitte, and numerous health technology companies. Through these roles, he has focused on translating research into practical tools and methods that support improved diagnostics, treatment development, and research strategy.
Philanthropy, Community Service, and Cultural Engagement
Philanthropy, Community Service, and Cultural Engagement
Richard Pestell has made community service and philanthropy a consistent part of his work in cancer care and academic leadership. At Georgetown and at Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives. These efforts helped strengthen patient-focused services while supporting programs that extend care and education into the community.
Richard Pestell has made community service and philanthropy a consistent part of his work in cancer care and academic leadership. At Georgetown and at Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives. These efforts helped strengthen patient-focused services while supporting programs that extend care and education into the community.
He has served on different boards, including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. His board work reflects ongoing involvement with cultural institutions, civic organizations, and public health-oriented initiatives.
He has served on different boards, including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. His board work reflects ongoing involvement with cultural institutions, civic organizations, and public health-oriented initiatives.
Richard supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. This effort connected fundraising with direct participation and reinforced the role of community-based support for wellness initiatives and cancer-related programs.
Richard supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. This effort connected fundraising with direct participation and reinforced the role of community-based support for wellness initiatives and cancer-related programs.
A Continuing Commitment to Science and Human Health
A Continuing Commitment to Science and Human Health
Richard Pestell now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and a member of the Wistar Institute Cancer Center. He continues to support global cancer programs, mentor scientific leaders, and develop technologies for improved diagnostics and treatment, maintaining a focus on translation, research integrity, and patient-centered outcomes.
Richard Pestell now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and a member of the Wistar Institute Cancer Center. He continues to support global cancer programs, mentor scientific leaders, and develop technologies for improved diagnostics and treatment, maintaining a focus on translation, research integrity, and patient-centered outcomes.
He continues to use scientific insight with a practical approach to enhance the quality of patient care and institutions, and to broaden the reach of modern oncology. Richard’s extensive work continues to influence cancer research, education, and biotechnology on a global scale through sustained leadership, continued research engagement, and a commitment to collaboration and service.
He continues to use scientific insight with a practical approach to enhance the quality of patient care and institutions, and to broaden the reach of modern oncology. Richard’s extensive work continues to influence cancer research, education, and biotechnology on a global scale through sustained leadership, continued research engagement, and a commitment to collaboration and service.
Dive Into Richard Pestell’s Philanthropy Here: https://richardpestell.com/philanthropy/
“Share hope. Hope sees the invisible, feels the intangible, and achieves the impossible—every day.”
To Know More Visit:
https://www.youtube.com/channel/UCxvxtNG-ZsBe0F8RJGI4W8Q
https://en.wikipedia.org/wiki/Richard_Pestell
https://www.pcarmrc.org/pestell-1
https://blumberginstitute.org/faculty/richard-g-pestell/
https://www.linkedin.com/in/richard-pestell-aa869352
https://www.cytodyn.com/newsroom/detail/632/cytodyn-appoints-richard-pestell-m-d-ph-d-as-lead
https://scholar.google.com/citations?user=6icYuFsAAAAJ
https://www.seakexperts.com/members/8904-richard-g-pestell
https://data.the-asci.org/controllers/asci/DirectoryController.php?action=profile&entryId=500154
https://research-repository.uwa.edu.au/en/persons/richard-pestell/
https://finance.yahoo.com/news/cytodyn-appoints-richard-pestell-m-133000105.html
https://www.healthgrades.com/physician/dr-richard-pestell-x59j3
https://www.youtube.com/channel/UCxvxtNG-ZsBe0F8RJGI4W8Q
https://orcid.org/0000-0003-3244-8777
https://www.ae-info.org/ae/Member/Pestell_Richard/CV
https://mdhs.unimelb.edu.au/engage/community/awards-and-honours/richard-george-pestell
https://www.pcarmrc.org/international-members-1
https://www.ae-info.org/ae/Member/Pestell_Richard
https://www.sbs.com.au/news/article/biotechnology-award-dr-richard-pestell/womarpd5d
https://www.pcarmrc.org/what-we-do
https://finance.yahoo.com/news/cytodyn-appoints-richard-pestell-m-133000105.html
https://research-repository.uwa.edu.au/en/persons/richard-pestell/
https://mta.hu/english/members-elected-to-the-hungarian-academy-of-sciences-in-2025-114411
Books and Publications Written by Richard Pestell:
Books and Publications Written by Richard Pestell:
Molecular Endocrinology: Basic Concepts and Clinical Correlations
Cancer Epigenetics: Biomolecular Therapeutics for Human Cancer
Prostate Cancer : Signaling Networks, Genetics, and New Treatment Strategies
Molecular Targeting and Signal Transduction (Cancer Treatment and Research, 119) 2004th Edition
Signal Transduction Protocols Kindle Edition
Molecular Targeting in Oncology
Cell Cycle Checkpoint Control Protocols (Methods in Molecular Biology, 241)
Prostate Cancer: Signalling Networks, Genetics and New Treatment Strategies [Book Review]
Signal Transduction Based Mouse Models of Prostate Cancer
About StromaGenesis and Precise Therapy Insights
About StromaGenesis and Precise Therapy Insights
StromaGenesis, LLC, founded in 2022 by Dr. Richard Pestell, is a clinical‑stage biotech company advancing precision oncology by targeting the tumor microenvironment. It has developed a proprietary prostate cancer prognostic algorithm and tissue‑ and blood‑based immunoassays that predict therapy response and act as companion diagnostics for solid tumors such as breast, colon, prostate, and glioblastoma.
The platform offers investors a scalable, de‑risked approach with multiple near‑to‑mid‑term opportunities in the growing precision‑medicine market.
To learn more, visit: www.stromagenesis.com
Page updated
Google Sites
Report abuse